Alnylam and The Medicines Co run PCSK9 race together through $205m alliance
This article was originally published in Scrip
With an exclusive global alliance worth up to $205 million plus double-digit royalties to develop and commercialize Alnylam Pharmaceuticals' ALN-PCS, the RNAi specialist and The Medicines Company are in a crowded field of companies with hypercholesterolemia therapies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), which regulates low-density lipoprotein (LDL).
You may also be interested in...
The Medicines Co. CEO Timney On Selling Inclisiran And Why Big Pharma Is Still Interested In CV Disease
Mark Timney took over the helm at The Medicines Company in December with a singular focus: wrapping up the Phase III program for inclisiran and finding a buyer for the cholesterol-lowering drug.
Restructuring Updates: Homology implemented modest job cuts as it ended a gene therapy trial, while ProQR revealed its second round of layoffs this year and Synthetic Biologics shifted focus to oncolytic virus pipeline. Also, Bolt, MacroGenics and others deprioritized programs in their Q2 updates.
The final Phase III readout for Ilaris (canakinumab) in NSCLC, this time in the adjuvant setting, missed the primary endpoint. One more lung cancer trial is under way, a Phase II neoadjuvant study.